medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2009, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2009; 56 (1)

Cholesterol levels in the North-Center part of Cuba. Related to urbanity?

Ruiz MAA, Odelín VL, Reyes JS, Burgos BD, Sarduy SJ

Language: Spanish
References: 35
Page: 18-26
PDF size: 88.73 Kb.


ABSTRACT

Objectives: To identify alternatives in cholesterol levels that constitutes risks for cardiovascular diseases, its relation with age and life styles imposed by urbanity, to understand the importance of early primary prevention in some groups of people. Methods: Transversal descriptive study developed in the North-Center part of Cuba between February 2006 and January 2008 that included 1,297 people at random chosen. To all of them total cholesterol was determined and were stratified according to risk categories. It was also analyzed the correlation between the total of habitants of urban zones, by municipalities, and the percentage of cholesterol of high risk. Results: From 15 to 35 years there was 8.31 percent of people with high risk cholesterol and from 36 to 60 years, 19.22 percent. The percentage of cholesterol of high risk varied from 2.11 in Quemado de Guines to 4.51 in Sagua la Grande. In the coastal region of Isabela de Sagua the percentage was very low. There was a strong positive relation between the high risk cholesterol levels and the whole number of people from urbanized zones. Conclusions: Special attention should be taken to the primary prevention of the coronary cardiopathy in people with ages between 36 to 60 years old where high percentages of high risk cholesterol occur. The group of 15 to 35 years old requires changes in their life styles that seem to be associated to the levels of cholesterol of high risk.


REFERENCES

  1. Mathers CD, Ezzati M, Jamison DT, Murray CJL (eds). Global burden of disease and risk factors. Washington, DC: World Bank; 2006.

  2. Organización Panamericana de la Salud. Análisis de Salud y Estadística. Base de datos de mortalidad. Washington, DC: OPS; 2006.

  3. Rodríguez T, Malvezzi M, Chatenoud L, Bosetti C, Levi F, Negri E et al. Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970–2000. Heart 2006; 92: 453–460.

  4. Dayspring TD. Prevention of a first myocardial infarction. J Clin Pharmacol 2001; 41 (4): 359-367.

  5. Hobbs FD. Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care. Eur J Gen Pract 2003; 9 (1): 16-24.

  6. Lasses LA, Torres JA, Salazar E. Dislipidemia en el anciano. Arch Cardiol Mex 2004; 74 (4): 315-326.

  7. Ciruzzi M, Schargrodsky H, Pramparo P, Rivas EE, Rodriguez NL, De la Noval GR et al. Attributable risk for acute myocardial infarction in four countries of Latin America. Med 2003; 63 (6): 697–703.

  8. Matorrás R, López A, Sanjurjo P, Ruiz JI, Echevarria Y, Nieto A et al. Ácido araquidónico en arteria umbilical y placenta en el retardo de crecimiento intrauterino. ¿Corroboración bioquímica de la hipótesis de Barker? Disponible en: http://db.doyma.es/cgi-bin/wdbcgi.exe/doyma

  9. Programa nacional de prevención, diagnóstico, evaluación y control de la hipertensión arterial. Comisión Nacional de Hipertensión Arterial. Rev Cub Med 1999; 38 (4): 219-246.

  10. Examen de salud para adultos. Disponible en: http://www.medicine21.com/doc.php?apartt=tecnicas&id=1668

  11. Cabalé MB, Sánchez D, Flores A. Control lipídico en pacientes dislipidémicos. Su asociación con complicaciones cardiovasculares. Rev Cub Med 2006; 45 (3). Disponible en: http://bvs.sld.cu/revistas/med/vol45_3_06/med05306.htm

  12. Second report of the expert panel on detection, evaluation, and treatment of blood cholesterol in adults, NIH Publication No. 93-3096; 1993.

  13. 13.Detección, valoración y tratamiento de la hipercolesterolemia en adultos. Rev Panam Sal Pub 2001; 9 (5): 338-344.

  14. Influencia de un Programa de Rehabilitación Integral en Pacientes Hipertensos-Obesos. Disponible en: http://www.efdeportes.com/efd59/rehaz.htm

  15. Anuario Estadístico de Salud en Cuba (1999). Disponible en: http://www.sld.cu/servicios/estadísticas/view.php?url= http%3A%2F%2Fbvs.sld.cu%2Fanuario%2Ftablas%2Ftabla/1999

  16. Russell R. The pathogenesis of atherosclerosis. N Engl J Med 1986; 314: 488-497. Consensus conference lowering blood cholesterol to prevent heart disease. JAMA 1985; 253: 2080-2086.

  17. Hernández E, Palomera A, Santos de F. Intervención psicológica en las enfermedades cardiovasculares. Guadalajara: Universidad de Guadalajara; 2003.

  18. Grau J, Hernández E. Psicología de la salud, fundamentos y aplicaciones. En: Grau J, Hernández E, Vera P (eds). Estrés, salud génesis y vulnerabilidad. Guadalajara, México: Centro Universitario de Ciencias de la Salud; 2005.

  19. Suárez VDM. Personalidad, cáncer y sobrevida. 2002, La Habana: Científico Técnica. Barra E. Influencia del estado emocional en la salud física. Terapia Psicológica 2003; 21 (1); 55-60.

  20. Tegos TJ. The genesis of atherosclerosis and risk factors: A review. Angiol 2001; 52 (2): 89-98.

  21. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann Vasc Surg 2005. Disponible en: http://www.ncbi.nlm.nih.gov/entrez

  22. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10 (2): 63-71.

  23. Robbie L, Lobby P. Inflammation and atherothrombosis. Ann NY Acad Sci 2001; 947: 167-79.

  24. Dieta y enfermedades cardiovasculares. Recomendaciones de la Sociedad Española de Arteriosclerosis. Disponible en: www.searteriosclerosis.org/recomendacions/recom 1-1htm

  25. Rodríguez AB, Salas M. Obesidad. En Álvarez SR. Temas de Medicina General Integral. La Habana: Editorial Ciencias Médicas; 2001. p. 867-871.

  26. Obesidad, problema de salud pública. Disponible en: www.facmed.unam.mx/pib c/ segundo/ guías/ referencias/ osp.pdf

  27. Jialal J, Scaccini C. Laboratory assessment of lipid, lipoproteins and apolipoproteins. In: Rifai N, Warnick GR (eds). Washington DC: AACC Press 1993; 17: 307-321.

  28. Holvoet P, Callen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB 1994; 8 (15): 1279-1284.

  29. Pereira G, Reyes A, Rodríguez A, Sánchez D, Domínguez E. Introducción de la determinación de “colesterol inmune” en la práctica investigativa de la aterosclerosis coronaria. Rev Cub Invest Biomed 2000; 19 (3): 181.

  30. Clapés S. Diabetes mellitus, estrés oxidativo y embarazo. Rev Cub Invest Biomed 2000; 19 (3): 192-193.

  31. Behrman RE, Kliegman RM, Harbin AM. Nelson Tratado de Pediatría Vol 1. 15a ed. Ciudad de la Habana: Editorial Ciencias Médicas; 1998. p. 475.

  32. Chao JC, Yuen MD, Chen PY, Chien SW. Vitamin C and E supplements improve the impaired antioxidant status and decrease plasma lipid peroxides in hemodialysis patients. J Nutr Biochem 2002; 13 (11): 653-663.

  33. Hoenyet K, Dagneli PC, Delaere K. Effect of a nutritional supplement containing vitamin E, selenium, vitamin C and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate. Eur Urol 2005; 47: 433-440.

  34. Thomas D. Vitamins in health and aging. Clin Geriatric Med 2004; 20 (2): 259-274.

  35. Penn M, Sapp S, Hsu A, Topol E. Use of antioxidant vitamins for the prevention of cardiovascular disease. Lancet 2003; 361 (9374): 2017-2023.




2020     |     www.medigraphic.com